GO
Loading...

Enter multiple symbols separated by commas

NPS Pharmaceuticals Inc

More

  • Feb 23- Rare disease drugmaker PTC Therapeutics Inc is exploring a potential sale amid takeover interest from several pharmaceutical companies, including Shire Plc and BioMarin Pharmaceutical Inc, according to people familiar with the matter. The stock of PTC Therapeutics, which has a market valuation of roughly $2 billion, rose as much as 25 percent to...

  • LONDON, Jan 26- Shire Plc shares gained more than 3 percent on Monday following news U.S. regulators had approved NPS Pharmaceuticals Inc's drug Natpara, validating Shire's decision to buy NPS for $5.2 billion.

  • Cramer: A hot biotech with a personal mission Wednesday, 21 Jan 2015 | 6:23 PM ET
    John Crowley, Amicus CEO

    This biotech roared 249 percent last year. Jim Cramer speaks with its CEO on his personal mission to find a cure for his daughters.

  • Cramer Remix: These oil stocks have bottomed Friday, 16 Jan 2015 | 7:13 PM ET

    Looking for opportunity in energy? "Mad Money" host Jim Cramer may have finally found the spot.

  • Cramer: The biotech that doubled in value last year Friday, 16 Jan 2015 | 6:23 PM ET
    Biotech

    Jim Cramer has his eye on this amazing biotech that doubled in value last year, and thinks it could have plenty more upside.

  • Cramer’s top biotech has enormous value creation Thursday, 15 Jan 2015 | 6:42 PM ET
    Biopharmaceutical

    This biotech just upped its guidance for 2015. Jim Cramer thinks it could have a lot more in the pipeline for profits.

  • Cramer Remix: Stay away from this stock Monday, 12 Jan 2015 | 7:11 PM ET
    Jim Cramer on Mad Money.

    "Mad Money" host Jim Cramer says this stock is too risky amid oil’s big decline.

  • Cramer: Ring the register on this hot biotech play Monday, 12 Jan 2015 | 6:58 PM ET
    Pharmaceutical production

    This hot biotech play is up more than 40 percent, and Jim Cramer thinks it's time to rake in profits.

  • *Alcoa shares up after the bell. Oil prices extended their recent free-fall after Goldman Sachs slashed its short-term price forecasts and Gulf producers showed no signs of curbing output. There's a lot of confusion and concern about the impact of oil prices, "said Tim Ghriskey, chief investment officer of Solaris Group in Bedford Hills, New York.

  • US stocks end lower with crude; Alcoa reports Monday, 12 Jan 2015 | 4:08 PM ET
    Trader on the floor of the New York Stock Exchange.

    Stocks dropped Monday after a second weekly loss.

  • NEW YORK, Jan 12- U.S. stocks fell on Monday, led by a decline in energy shares as oil prices fell further while concern grew ahead of the start of corporate earnings season. Brent was down more than 5 percent to $47.44 and U.S. crude down 4.6 percent at $46.13, as Goldman Sachs slashed its short-term price forecasts and Gulf producers showed no signs of curbing output.

  • Private equity, hedge fund stocks to outperform? Monday, 12 Jan 2015 | 10:04 AM ET
    Pedestrians walk outside an E*Trade Financial office in New York.

    Major investment banks and money center banks are not the best way to play Wall Street's success six years into a bull market, JMP Securities said.

  • *Foundation Medicine jumps; Roche to take majority stake. Oil prices continued their downward march and weighed on equities, with both Brent and U.S. crude down about 4 percent as Goldman Sachs slashed its short-term price forecasts and Gulf producers showed no signs of curbing output. "During this cycle, since the beginning of the precipitous selloff in the...

  • *Foundation Medicine jumps; Roche to take majority stake. Oil prices continued their downward march and helped weaken futures, with Brent down 3.8 percent to $48.20 and U.S. crude down 3.7 percent to $46.59 as Goldman Sachs slashed its short-term price forecasts and Gulf producers showed no signs of curbing output. "During this cycle, since the beginning of the...

  • *Foundation Medicine jumps; Roche to take majority stake. NEW YORK, Jan 12- U.S. stock index futures rose on Monday, after a two-week decline pushed the S&P 500 back into negative territory for the year, as investors anticipated the start of the corporate earnings season. *Alcoa is scheduled to post quarterly earnings after the closing bell, with financials JPMorgan...

  • Early movers: TIF, DLTR, CZR, MS, GM & more Monday, 12 Jan 2015 | 7:58 AM ET
    Trader on the floor of the New York Stock Exchange.

    Some of the names on the move ahead of the open.

  • US STOCKS-Futures climb after two-week drop Monday, 12 Jan 2015 | 7:35 AM ET

    *Foundation Medicine jumps; Roche to take majority stake. NEW YORK, Jan 12- U.S. stock index futures rose on Monday, after a two-day decline pushed the S&P 500 back into negative territory for the year, as investors anticipated the start of the corporate earnings season. *Alcoa is scheduled to post quarterly earnings after the closing bell, with financials JPMorgan...

  • Goldman Sachs: Watch out for energy M&A in 2015 Monday, 12 Jan 2015 | 7:14 AM ET
    A derrick hand removes the the plastic caps off the threaded ends of pipe used in the drilling process in Knox County, Ohio.

    Healthcare M&A looks set to be strong again this year, following deals from Shire and Roche. But Goldman Sachs says energy's a sector to watch too.

  • *Peugeot buoyed by broker upgrade. LONDON, Jan 12- European equities gained on Monday, led by rising healthcare stocks, after Shire agreed to buy NPS Pharmaceuticals for $5.2 billion and Roche also struck a deal. Chemicals shares also performed well after U.S. investment bank Citigroup upgraded several European chemicals companies, including BASF.

  • *European shares rise as Shire buys NPS Pharmaceuticals. The pan-European FTSEurofirst 300 index rose 0.3 percent to 1,352.67 points after Shire Plc agreed to buy NPS Pharmaceuticals for $5.2 billion. The euro zone's blue-chip Euro STOXX 50 index advanced 0.6 percent and Britain's FTSE 100 climbed 0.3 percent, helped by a 1.4 percent rise in Shire.